Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Print view.
German.
Contact.
Data entry.
Start.
Open Access.

Navigation/Search

Researchers.
Institutions.
Projects.
Publications.
Partners.
Sponsors.
Equipment.
Knowhow.
Fields of Research.

Selected Publication:

Liutkevych, K.
Dupilumab (Dupixent®): Efficacy and treatment satisfaction in patients with atopic dermatitis
Humanmedizin; [ Diplomarbeit ] Medizinische Universität Graz; 2024. pp.

Authors Med Uni Graz:
Advisor:: Legat Franz; Repelnig Maria-Lisa
Altmetrics:
Abstract:: Atopic dermatitis (AD) is the most common chronic inflammatory skin condition worldwide. In 2017, dupilumab was approved in the EU for use in moderate to severe forms of AD, providing a reliable long-term therapy and relief of disease symptoms. Alongside the reduction of the symptoms, it offered a long-lasting improvement in quality of life, reducing itch and sleep disturbances. As of 2020, there was no data from Austria regarding the long-term use of dupilumab for this indication.